Thomas Stuckey, MD
Ophthalmology · Baton Rouge, LANPI 1437177300
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 211 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Alcon at 50.0% of the total.
Across 211 payments — averaging $27.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- Biotissue Holdings Inc.$672
- AbbVie$440
- Bausch & Lomb, A Division Of Bausch Health US, LLC$291
- Aerie Pharmaceuticals, Inc.$277
- Rxsight Inc$266
- plus $913 from 16 others
Across 3 payments — averaging $7333.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$22K
What the payments were for
- Food & beverage$5,59598%
- Education$801%
- Gifts$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 97 | $2,860 |
| Biotissue Holdings Inc. | 16 | $672 |
| AbbVie(2 entities) | 19 | $440 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 16 | $291 |
| Aerie Pharmaceuticals, Inc. | 14 | $277 |
| Rxsight Inc | 7 | $266 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $200 |
| Bausch & Lomb Americas Inc. | 8 | $163 |
| Glaukos Corporation | 3 | $112 |
| Sight Sciences, Inc. | 4 | $73 |
| Oyster Point Pharma, Inc. | 3 | $59 |
| Harrow Eye, LLC | 2 | $50 |
| Ocular Therapeutix, Inc. | 3 | $43 |
| NEW World Medical,inc. | 3 | $38 |
| Tarsus Pharmaceuticals, Inc. | 1 | $32 |
| Dompe US, Inc. | 1 | $28 |
| Amgen | 1 | $24 |
| Novartis | 1 | $24 |
| Mallinckrodt Enterprises LLC | 1 | $22 |
| Eyepoint US, Inc. | 1 | $16 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| Ivantis, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$536
- AcrySof IQ PanOptix$256
- Prokera$169
- ARGOS$148
- AcrySof$144
- ReSTOR$139
- LenSx$132
- RXSIGHT CONTACT LENS$107
- RXSIGHT INJECTOR CARTRIDGE$107
- RXSIGHT INJECTOR HANDPIECE$107
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$107
- LIGHT ADJUSTABLE LENS (LAL)$107
How this compares
$5,720 in reported general payments places this provider in the 80th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 61 | $23,423 |
| RhopressaNetarsudil Mesylate | 39 | $19,266 |
| CombiganBrimonidine Tartrate/Timolol | 41 | $11,376 |
| RestasisCyclosporine | 15 | $9,462 |
| Brimonidine Tartrate | 81 | $7,175 |
| Prednisolone Acetate | 114 | $4,456 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 34 | $4,173 |
| Latanoprost | 315 | $3,315 |
| Ketorolac Tromethamine | 116 | $2,541 |
| Travoprost | 13 | $1,635 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 114 | $1,596 |
| Timolol Maleate | 93 | $924 |
| Dorzolamide Hcl | 37 | $890 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 64 | $817 |
| MoxifloxacinMoxifloxacin Hcl | 14 | $224 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis | $440 | $44,261117 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $277 | $19,26639 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 286 ophthalmology providers in Louisiana.
Other ophthalmology in Baton Rouge
- Blake WilliamsonBaton Rouge$443K
- Charles WilliamsonBaton Rouge$16K
- David FargasonBaton Rouge$6K
- Philip EhrlichBaton Rouge$6K
- Daniel NelsonBaton Rouge$6K
- Michael MorganBaton Rouge$6K
- George FivgasBaton Rouge$6K
- Devin TranBaton Rouge$5K
- Rebecca MetzingerNew Orleans$63K
- Ze ZhangNew Orleans$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.